Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (221-230 of 512) with videos related to

Pageof 52
Sort By:
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
Cancers|December 8, 2020
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung CancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.
JTO Clinical and Research Reports|January 8, 2026
Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief ReportAdele Bonato, Claudia Parisi, Priscilla Cascetta, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie studyNicolas Epaillard, Jose Carlos Benitez, Teresa Gorria, et al.
Oncotarget|April 28, 2017
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patientsAngela Boros, Ludovic Lacroix, Benjamin Lacas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2026
Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancerDanny Lavigne, Cecile Le Péchoux, Angela Botticella, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2012
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinomaNader Abedallaa, Lise Tremblay, Charlotte Baey, et al.
Cancer Treatment Reviews|September 10, 2023
Local control strategies for management of NSCLC with oligoprogressive diseaseAntoine Mavrikios, Jordi Remon, Clément Quevrin, et al.
Ecancermedicalscience|October 21, 2020
Perspectives on cancer care in older patients in FranceMathilde Hauchecorne, Monica Pierro, Etienne Brain, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Pageof 52

Showing results (221-230 of 512) with videos related to

Sort By:
Pageof 52
The Lancet. Oncology|September 19, 2017
Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trialDavid Planchard, Egbert F Smit, Harry J M Groen, et al.
Cancers|December 8, 2020
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung CancerBoris Duchemann, Jordi Remon, Marie Naigeon, et al.
JTO Clinical and Research Reports|January 8, 2026
Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief ReportAdele Bonato, Claudia Parisi, Priscilla Cascetta, et al.
Lung Cancer (Amsterdam, Netherlands)|April 2, 2021
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie studyNicolas Epaillard, Jose Carlos Benitez, Teresa Gorria, et al.
Oncotarget|April 28, 2017
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patientsAngela Boros, Ludovic Lacroix, Benjamin Lacas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2026
Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancerDanny Lavigne, Cecile Le Péchoux, Angela Botticella, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2012
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinomaNader Abedallaa, Lise Tremblay, Charlotte Baey, et al.
Cancer Treatment Reviews|September 10, 2023
Local control strategies for management of NSCLC with oligoprogressive diseaseAntoine Mavrikios, Jordi Remon, Clément Quevrin, et al.
Ecancermedicalscience|October 21, 2020
Perspectives on cancer care in older patients in FranceMathilde Hauchecorne, Monica Pierro, Etienne Brain, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Pageof 52